Supplementary Table S4 from Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Year: 2025
Type: supplementary-materials
Abstract: Supplemental Table 4: Treatment-emergent ≥Grade 3 AEs by PT Occurring in ≥3% of Total Population
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4408122189